Josh Baxt

Analysis shows that persistence is paying off for drug developers, driven by the rise of CAR-T and other gene therapy, newly discovered cancer targets, better patient identification methods-and the realization that failures have their place in shaping the pipeline of tomorrow.

Josh Baxt casts his eye over what to look out for in the diabetes and obesity treatment markets.

The heart failure health area is set to expand from $2.9 billion in 2013 to $8.9 billion in 2023, writes Josh Baxt.

The science of drug discovery is back on script-and the stars are cued up for a new generation of breakthrough therapies. But is pharma ready to raise its game and cut a deal with all those "prove it to me" payers?